- 询价
- MedChemExpress(MCE)
- 美国
- HY-144737
- 2025年07月13日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Please store the product under the recommended conditions in the Certificate of Analysis.
- 库存：
货期：电询
- 供应商：
MedChemExpress LLC
- CAS号：
474516-87-5
- 规格：
电询
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Anti-inflammatory agent 15
CAS No. : 474516-87-5
MCE 国际站：Anti-inflammatory agent 15
产品活性：Anti-inflammatory agent 15 (化合物 29) 是一种有效的抗结核分枝杆菌和抗炎剂。Anti-inflammatory agent 15 抑制 Mtb H37Rv 和 M299 生长，其 MIC50 (最低抑制浓度 50%) 分别为 2.3 和 7.8 μM。Anti-inflammatory agent 15 通过抑制 iNOS 表达抑制 NO，同时抑制 TNF-α 和 IL-1β 的产生。Anti-inflammatory agent 15 可用于结核病的研究。
研究领域：Anti-infection | Apoptosis
作用靶点：Bacterial | TNF Receptor
In Vitro: Anti-inflammatory agent 15 (compound 29) is active in the reduction of accumulated nitrite, with an IC50 of 71.7 ± 1.1 μM.
相关产品：Rapamycin | Doxorubicin hydrochloride | Bafilomycin A1 | Dexamethasone | Puromycin dihydrochloride | Dimethyl sulfoxide | Staurosporine | Actinomycin D | G-418 disulfate | Etoposide | Resatorvid | 5-Azacytidine | Nigericin sodium salt | Brefeldin A | Estradiol | CCCP | Ionomycin | Resveratrol | Hygromycin B | Tunicamycin | Mitomycin C | Everolimus | Doxycycline hyclate | Tacrolimus | Methotrexate | Neomycin sulfate | Acetaminophen | Streptozotocin | Anisomycin
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验as an effective strategy for management of many different human diseases. The active agent used to procure gene therapy is likely to consist of oligonucleotides, ribozymes, or a DNA sequence that can be transcribed into a message capable of eliciting a therapeutic
Chemoprevention of Lung Cancer
and non steroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for colon cancer“ (1 ). This somewhat pessimistic statement reflects the outcome of several clinical trials that examined whether human lung cancer could effectively be prevented
Inflammatory Mediators in CF Patients
of the same patient over time) before and after an anti-infective or anti-inflammatory intervention (13 -15 ). With many new anti-inflammatory and other treatments being proposed for CF lung disease, it is imperative to have a safe and standardized way of sampling
技术资料暂无技术资料 索取技术资料
